Analyst Tracker/Benjamin Burnett

Benjamin Burnett

Q: How accurate are Benjamin Burnett's stock ratings?

About 60% of Benjamin's ratings were profitable over a one-year hold, with an average return of +10.6% per rating, measured by 13Foresight from historical prices.

Q: How is Benjamin ranked?

Benjamin Burnett is ranked #793 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Wells Fargo

Wall Street Analyst

★★★★☆

#793

on 13Foresight · ranked by our own returns

60%

Success Rate

+10.7%

Average Return

37 of 62 calls profitable · +4.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 60% of Benjamin Burnett's ratings turned a profit when each position was held for 1 year — averaging +10.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

100 Buy 21 Hold 0 Sell

Benjamin's Stock Coverage 38 ratings · 2026-08-08

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
PRAX Praxis Precision Medicines	Aug 07, 2026	HOLD	Strong Buy +50.2% avg upside 24 analysts	$362.00 3.85% Downside	·	·
TECX Tectonic Therapeutic	Aug 07, 2026	BUY	Strong Buy +82.5% avg upside 24 analysts	$93.00 203.07% Upside	+0.0%	·
AMPH Amphastar Pharmaceuticals	Aug 07, 2026	HOLD	Hold +24.7% avg upside 11 analysts	$20.00 3.90% Downside	·	·
INSM Insmed	Aug 06, 2026	BUY	Strong Buy +34.9% avg upside 37 analysts	$169.00 29.76% Upside	-1.1%	·
UTHR United Therapeutics	Aug 06, 2026	BUY	Buy -19.7% avg upside 26 analysts	$700.00 32.82% Upside	+0.0%	·
RARE Ultragenyx Pharmaceutical	Aug 05, 2026	BUY	Strong Buy +157.0% avg upside 36 analysts	$45.00 71.97% Upside	+2.6%	·
CMPS COMPASS Pathways	Aug 05, 2026	HOLD	Strong Buy +63.9% avg upside 20 analysts	$13.00 6.87% Downside	+0.0%	·
MNKD MannKind	Aug 05, 2026	BUY	Buy +73.6% avg upside 22 analysts	$13.00 233.41% Upside	+0.0%	·
KROS Keros Therapeutics	Aug 03, 2026	BUY	Strong Buy +117.5% avg upside 21 analysts	$18.00 67.59% Upside	-1.1%	·
PTCT PTC Therapeutics	Jul 31, 2026	BUY	Strong Buy +11.3% avg upside 29 analysts	$106.00 47.72% Upside	+3.6%	·
WVE Wave Life Sciences	Jul 30, 2026	BUY	Strong Buy +238.5% avg upside 28 analysts	$14.00 129.42% Upside	+4.7%	·
ALKS Alkermes	Jul 29, 2026	BUY	Strong Buy -15.2% avg upside 34 analysts	$65.00 32.51% Upside	+0.1%	·
DFTX Definium Therapeutics	Jul 27, 2026	BUY	Strong Buy +2.1% avg upside 21 analysts	$68.00 39.06% Upside	+8.2%	·
GHRS GH Research	Jul 27, 2026	BUY	Strong Buy +28.7% avg upside 12 analysts	$44.00 41.03% Upside	+0.9%	·
HELP Helus Pharma	Jul 27, 2026	BUY	Strong Buy +225.4% avg upside 13 analysts	$16.00 43.23% Upside	+50.8%	·
AXSM Axsome Therapeutics	Jun 10, 2026	BUY	Strong Buy +9.4% avg upside 29 analysts	$255.00 20.55% Upside	-13.6%	·
LQDA Liquidia Technologies	Jun 04, 2026	BUY	Strong Buy -30.0% avg upside 15 analysts	$62.00 31.15% Downside	+44.3%	·
XENE Xenon	Jun 01, 2026	BUY	Strong Buy -1.9% avg upside 28 analysts	$69.00 9.49% Upside	+18.6%	·
SVRA Savara	May 22, 2026	BUY	Strong Buy +48.5% avg upside 17 analysts	$9.00 52.60% Upside	+16.1%	·
RAPP Rapport Therapeutics, Inc.	Apr 22, 2026	BUY	Strong Buy +21.1% avg upside 14 analysts	$46.00 1.60% Downside	+23.7%	·
RVMD Revolution Medicines	Apr 01, 2025	BUY	Strong Buy -19.4% avg upside 32 analysts	$64.00 68.16% Downside	+193.4%	·
CABA Cabaletta Bio	Mar 31, 2025	BUY	Strong Buy +399.3% avg upside 16 analysts	$13.00 369.25% Upside	+94.2%	·
PGEN Precigen	Mar 20, 2025	BUY	Strong Buy +247.5% avg upside 11 analysts	$7.00 1.43% Downside	+82.2%	·
ALLO Allogene Therapeutics	Mar 17, 2025	HOLD	Strong Buy +663.0% avg upside 28 analysts	$4.00 104.06% Upside	+22.7%	·
IOVA Iovance Biotherapeutics	Mar 17, 2025	BUY	Buy +108.7% avg upside 24 analysts	$18.00 174.79% Upside	+4.0%	·
ATRA Atara Biotherapeutics	Mar 11, 2025	HOLD	Buy +115.8% avg upside 18 analysts	$3.00 63.57% Downside	-5.8%	·
FATE Fate Therapeutics	Mar 06, 2025	HOLD	Buy +343.8% avg upside 31 analysts	$3.00 17.62% Upside	+27.9%	·
IRON Disc Medicine	Mar 03, 2025	BUY	Strong Buy +12.2% avg upside 21 analysts	$92.00 17.30% Upside	+18.5%	·
JSPR Jasper Therapeutics	Mar 02, 2025	BUY	Strong Buy +4495.4% avg upside 17 analysts	$80.00 12281.89% Upside	-75.8%	·
CRSP Crispr Therapeutics AG	Feb 13, 2025	HOLD	Buy +43.2% avg upside 41 analysts	$49.00 7.82% Downside	+22.0%	·
IDYA IDEAYA Biosciences	Nov 06, 2024	BUY	Strong Buy +32.1% avg upside 29 analysts	$64.00 75.03% Upside	-1.8%	·
EFTR eFFECTOR Therapeutics	Apr 19, 2024	BUY	Strong Buy +66249900.1% avg upside 5 analysts	$10.00 4999900.02% Upside	·	·
DTIL Precision BioSciences	Aug 16, 2023	BUY	Strong Buy +215.7% avg upside 12 analysts	$42.00 456.24% Upside	-43.9%	·
SGMOQ Sangamo Therapeutics	Aug 10, 2023	HOLD	Buy +9961.3% avg upside 16 analysts	$3.60 3128.77% Upside	·	·
NKTR Nektar Therapeutics	Mar 02, 2023	HOLD	Buy -1.2% avg upside 26 analysts	$3.00 95.90% Downside	-49.4%	·
NGNE Neurogene	Nov 15, 2022	HOLD	Strong Buy +39.4% avg upside 23 analysts	$4.50 87.64% Downside	+62.4%	·
GNCAQ Genocea Biosciences	Apr 29, 2022	HOLD	Strong Buy +573999900.0% avg upside 10 analysts	$0.16 15999899.95% Upside	·	·
BEAM Beam Therapeutics	Feb 28, 2022	BUY	Strong Buy +88.8% avg upside 25 analysts	$120.00 331.35% Upside	-48.6%	·

🔒 33 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Benjamin Burnett — Frequently Asked Questions

How accurate are Benjamin Burnett's stock ratings?

Based on the calls 13Foresight could measure, about 60% of Benjamin's ratings were profitable over a one-year hold, with an average return of +10.6% per rating, or +4.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Benjamin ranked on 13Foresight?

Benjamin Burnett is currently ranked #793 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Benjamin cover?

Benjamin most recently has ratings on PRAX, TECX, AMPH, INSM, UTHR, RARE, CMPS, MNKD, KROS, PTCT, WVE, ALKS and 26 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Benjamin Burnett

Rating Distribution

Welcome to 13Foresight!